week 5 of tirzepatide WEIGH IN it’s officially week 5 of
Description
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
Available from: GLP-1 agonists (e.g
You experience the same effects whether your dose comes from a 5 mg vial or a 60 mg vial
Submitting payment does not guarantee approval
Key Takeaways In the first head-to-head trial (SURMOUNT-5, NEJM 2025), tirzepatide produced 20.2% average weight loss vs
It says units
